Cargando…

Intensity of antiplatelet therapy and percutaneous coronary intervention

Thienopyridine derivatives such as clopidogrel have been shown to reduce the incidence of death in patients undergoing percutaneous coronary intervention when used in conjunction with aspirin. Recently, a new thienopyridine, prasugrel, significantly reduced the primary endpoint of cardiovascular dea...

Descripción completa

Detalles Bibliográficos
Autor principal:	Aronow, Wilbert S
Formato:	Texto
Lenguaje:	English
Publicado:	Medicine Reports Ltd 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920701/ https://www.ncbi.nlm.nih.gov/pubmed/20948699 http://dx.doi.org/10.3410/M1-8

Ejemplares similares

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Eccentric hypertrophy predicts adverse events in patients undergoing percutaneous coronary intervention for acute coronary syndrome
por: Ha, Edward T., et al.
Publicado: (2021)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes
por: Shlofmitz, Evan, et al.
Publicado: (2019)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy
por: Patail, Haris, et al.
Publicado: (2023)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
por: Mourikis, Philipp, et al.
Publicado: (2023)

Heightened risk of cardiac events following percutaneous coronary intervention for cocaine-associated myocardial infarction
por: Chen, Ching Wei Russell, et al.
Publicado: (2019)

Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
por: Ostojic, Zvonimir, et al.
Publicado: (2021)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
por: Remillard, Taylor C., et al.
Publicado: (2021)

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
por: Wang, Yehua, et al.
Publicado: (2023)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome: Practical lessons from a review
por: ten Berg, J. M., et al.
Publicado: (2017)

The effect of cardiac geometry variation according to sex and race on outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Ha, Edward T., et al.
Publicado: (2021)

The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”
por: Kang, Jeehoon, et al.
Publicado: (2018)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Percutaneous Coronary Intervention With Dual Antiplatelet Therapy in a Patient With Chronic Subdural Hematoma: Novel Approach
por: Etuk, Aniekeme S, et al.
Publicado: (2022)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
por: ZHOU, HONG, et al.
Publicado: (2013)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
por: Kwok, Chun Shing, et al.
Publicado: (2014)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Hyphema: A Rare Complication of Periprocedural Antiplatelets and Anticoagulants Following Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?
por: Abdulrahman, Balen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_091ccsqkru8f8sgic994hia8ir